Attendee search 

MAVIE Technologies is an investment banking boutique in Chinese-Western healthcare transactions providing commercially-focused, end to end advice to maximize deal certainty and increase the intended value of transactions. Our team combines deal structuring sophistication and experience - whether it is private placement, secondary shares sale, joint-venture, licensing or M&A - with deep Chinese healthcare insights, strategic thinking and proprietary access. We add unique value in visualizing, negotiating and closing the deal.

Cytovance® Biologics is a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO) that excels in the rapid and cost-effective development and manufacture of large molecule APIs from both mammalian cell culture and microbial fermentation such as monoclonal antibodies, fragment antibodies, bispecifics, enzymes, fusion proteins, vaccines and other biological products including plasmid DNA and cell-based therapeutics. In addition to our clinical and commercial cGMP API manufacturing services, Cytovance offers well integrated development services supporting the entire product lifecycle including cell line development, cell banking, microbial strain development, process and analytical development, and process characterization. A centralized, responsive program management team coordinates all critical CMC activities for each client program around raw materials management, QC testing, ICH stability studies, and regulatory support. Our 140,000 sq. ft. state-of-the-art facilities in Oklahoma City are designed to meet U.S., EU, and other global regulatory standards.

About Rius Medical: Rius Medical is designing and developing a new generation of Commercial cell therapies positioned at the crossroads of two high-potential programs: (1.) genetically engineering red blood cells for an entirely new class of cellular medicines and (2.) potent NK-cell therapy products. Due to their mechanism of action, engineered red blood cells demonstrated treatments for wide range of patients from starving cancer cells to targeting autoimmune diseases. Building on exceptional progress in cell therapies, Rius Medical is in a unique position to offer Third-Generation red blood cells for drug delivery that addresses Rare Diseases, Oncology and Autoimmune Diseases like type 1 diabetes! Furthermore, harnessing the unique power of natural killer (NK) cells enables the treatment of cancer and infectious diseases such as Influenza virus or SARS-Coronavirus (i.e. COVID-19 pandemic). That’s right, NK-cells as vaccine delivery NOT for antibodies but for “memory T cells” activation!

RA/QA and clinical services consultancy company dedicated to medical devices.
We have been providing services to a wide variety of medical devices in every Class to prepare technical documents for CE certification and FDA authorization.
Services that are sought most are
Compiling or updating Technical Files according to MDR (EU 2017/745) and IVDR (EU 2017/746)
CEP, CER, PMCF Plan, Clinical Trial Protocols
QMS updates
Sterilization Validation, Process Validation, Packaging Validation, Software Validation, etc.
GAP, Mock, Supplier Audits
Medical device registration in 140 countries

Armoured hold the Tianyi Group layout of science and technology investment capital investment platform. Armoured capital in order to create long-term value for the purpose, committed to accelerate the transformation of scientific and technological industry and fall to the ground, accelerate the development of innovative enterprise, and industry potential industry and change. So far, has invested Zephyrm Biotechnologies, Milky Way motivation, CSTshen, companies such as the future and will continue to pay attention to the capitalization of the business process and industry, seek the change from a single financial investment to the strategy of diversifying investment.

NGO

Humanwell is the market leader in anaesthetics/analgesics, fertility regulation drugs, and Uyghur medicine in Asia. It is also a major player with expanding product portfolio and market shares in treating central nerve system, respiratory and dermatological diseases in China.

Harbour BioMed is a global, clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics in the areas of oncology and immunological diseases to address unmet patient’s needs.